Steven Szabo
Psychiatry · Durham, NCNPI 1033352919
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $312,462 of the $360,423 with a category attached, or 86.7%. 14 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 29.1% of the total. Reporting peaked in 2019 at $359,673 and has fallen 100.0% since, to $108 in 2025. Among psychiatry clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 482 payments — averaging $747.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$105K
- Otsuka America Pharmaceutical, Inc.$104K
- Johnson & Johnson$79K
- Avanir Pharmaceuticals, Inc.$69K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$3K
- Teva Pharmaceuticals USA, Inc.$335
- plus $707 from 8 others
Across 2 payments — averaging $25,628 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Otsuka Pharmaceutical Development & Commercialization, Inc.$51K
What the payments were for
- Consulting fees$3,0001%
- Speaking & faculty fees$312,46287%
- Travel & lodging$36,54910%
- Food & beverage$8,4112%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 167 | $104,920 |
| Otsuka America Pharmaceutical, Inc. | 142 | $104,365 |
| Johnson & Johnson | 74 | $78,513 |
| Avanir Pharmaceuticals, Inc. | 65 | $68,890 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 6 | $2,693 |
| Teva Pharmaceuticals USA, Inc. | 11 | $335 |
| Acadia Pharmaceuticals Inc | 4 | $157 |
| Axonics, Inc. | 2 | $153 |
| Lundbeck LLC | 5 | $137 |
| AbbVie | 2 | $120 |
| Sunovion Pharmaceuticals Inc. | 1 | $100 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| GSK | 1 | $14 |
| Coopersurgical, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$102,071
- REXULTI$101,765
- SPRAVATO$76,764
- NUEDEXTA$68,167
- INVEGA TRINZA$251
- INVEGA SUSTENNA$251
- Bulkamid$119
How this compares
$360,423 in reported general payments places this provider in the 95th percentile of 1,108 psychiatry providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other psychiatry in Durham
- Mark ReynoldsDurham$3.2M
- Andrew KrystalDurham$234K
- Ranjan SudanDurham$81K
- Caleb WhitenackDurham$68K
- Paolo MannelliDurham$38K
- P DoraiswamyDurham$35K
- David JarrettDurham$28K
- Steven PrakkenDurham$22K
- Mustafa HusainDurham$20K
- Damon TweedyDurham$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.